Proficiency testing of human leukocyte antigen-DR and human leukocyte antigen-DQ genetic risk assessment for type 1 diabetes using dried blood spots

Paul Dantonio, Nancy Meredith-Molloy, William A. Hagopian, Jin-Xiong She, Beena Akolkar, Suzanne K. Cordovado, Miyono Hendrix, L. Omar Henderson, W. Harry Hannon, Robert F. Vogt

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: The plurality of genetic risk for developing type 1 diabetes mellitus (T1DM) lies within the genes that code for the human leukocyte antigens (HLAs). Many T1DM studies use HLA genetic risk assessment to identify higher risk individuals, and they often conduct these tests on dried blood spots (DBSs) like those used for newborn bloodspot screening. One such study is The Environmental Determinants of Diabetes in the Young (TEDDY), a long-term prospective study of environmental risk factors. To provide quality assurance for T1DM studies that employ HLA genetic risk assessment, the Centers for Disease Control and Prevention (CDC) conducts both a voluntary quarterly proficiency testing (VQPT) program available to any laboratory and a mandatory annual proficiency testing (PT) challenge for TEDDY laboratories. Methods: Whole blood and DBS samples with a wide range of validated HLA-DR and HLA-DQ genotypes were sent to the participating laboratories. Results were evaluated on the basis of both the reported haplotypes and the HLA genetic risk assessment. Results: Of the reported results from 24 panels sent out over six years in the VQPT, 94.7% (857/905) were correctly identified with respect to the relevant HLA-DR or HLA-DQ alleles, and 96.4% (241/250) were correctly categorized for risk assessment. Significant improvement was seen over the duration of this program, usually reaching 100% correct categorization during the last three years. Of 1154 reported results in four TEDDY PT challenges, 1153 (99.9%) were correctly identified for TEDDY eligibility. Conclusions: The different analytical methods used by T1DM research centers all provided accurate (>99%) results for genetic risk assessment. The two CDC PT programs documented the validity of the various approaches to screening and contributed to overall quality assurance.

Original languageEnglish (US)
Pages (from-to)929-941
Number of pages13
JournalJournal of Diabetes Science and Technology
Volume4
Issue number4
DOIs
StatePublished - Jan 1 2010

Fingerprint

Antigens
Medical problems
HLA Antigens
Type 1 Diabetes Mellitus
Risk assessment
Blood
Testing
Disease control
Centers for Disease Control and Prevention (U.S.)
Quality assurance
Screening
Haplotypes
Genes
Alleles
Genotype
Prospective Studies
Research

Keywords

  • Newborn screening
  • Quality assurance
  • Quality control
  • The environmental determinants of diabetes in the young

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Bioengineering
  • Biomedical Engineering

Cite this

Proficiency testing of human leukocyte antigen-DR and human leukocyte antigen-DQ genetic risk assessment for type 1 diabetes using dried blood spots. / Dantonio, Paul; Meredith-Molloy, Nancy; Hagopian, William A.; She, Jin-Xiong; Akolkar, Beena; Cordovado, Suzanne K.; Hendrix, Miyono; Henderson, L. Omar; Hannon, W. Harry; Vogt, Robert F.

In: Journal of Diabetes Science and Technology, Vol. 4, No. 4, 01.01.2010, p. 929-941.

Research output: Contribution to journalArticle

Dantonio, P, Meredith-Molloy, N, Hagopian, WA, She, J-X, Akolkar, B, Cordovado, SK, Hendrix, M, Henderson, LO, Hannon, WH & Vogt, RF 2010, 'Proficiency testing of human leukocyte antigen-DR and human leukocyte antigen-DQ genetic risk assessment for type 1 diabetes using dried blood spots', Journal of Diabetes Science and Technology, vol. 4, no. 4, pp. 929-941. https://doi.org/10.1177/193229681000400424
Dantonio, Paul ; Meredith-Molloy, Nancy ; Hagopian, William A. ; She, Jin-Xiong ; Akolkar, Beena ; Cordovado, Suzanne K. ; Hendrix, Miyono ; Henderson, L. Omar ; Hannon, W. Harry ; Vogt, Robert F. / Proficiency testing of human leukocyte antigen-DR and human leukocyte antigen-DQ genetic risk assessment for type 1 diabetes using dried blood spots. In: Journal of Diabetes Science and Technology. 2010 ; Vol. 4, No. 4. pp. 929-941.
@article{3bc81c192ab149c3b399b42050bf36b9,
title = "Proficiency testing of human leukocyte antigen-DR and human leukocyte antigen-DQ genetic risk assessment for type 1 diabetes using dried blood spots",
abstract = "Background: The plurality of genetic risk for developing type 1 diabetes mellitus (T1DM) lies within the genes that code for the human leukocyte antigens (HLAs). Many T1DM studies use HLA genetic risk assessment to identify higher risk individuals, and they often conduct these tests on dried blood spots (DBSs) like those used for newborn bloodspot screening. One such study is The Environmental Determinants of Diabetes in the Young (TEDDY), a long-term prospective study of environmental risk factors. To provide quality assurance for T1DM studies that employ HLA genetic risk assessment, the Centers for Disease Control and Prevention (CDC) conducts both a voluntary quarterly proficiency testing (VQPT) program available to any laboratory and a mandatory annual proficiency testing (PT) challenge for TEDDY laboratories. Methods: Whole blood and DBS samples with a wide range of validated HLA-DR and HLA-DQ genotypes were sent to the participating laboratories. Results were evaluated on the basis of both the reported haplotypes and the HLA genetic risk assessment. Results: Of the reported results from 24 panels sent out over six years in the VQPT, 94.7{\%} (857/905) were correctly identified with respect to the relevant HLA-DR or HLA-DQ alleles, and 96.4{\%} (241/250) were correctly categorized for risk assessment. Significant improvement was seen over the duration of this program, usually reaching 100{\%} correct categorization during the last three years. Of 1154 reported results in four TEDDY PT challenges, 1153 (99.9{\%}) were correctly identified for TEDDY eligibility. Conclusions: The different analytical methods used by T1DM research centers all provided accurate (>99{\%}) results for genetic risk assessment. The two CDC PT programs documented the validity of the various approaches to screening and contributed to overall quality assurance.",
keywords = "Newborn screening, Quality assurance, Quality control, The environmental determinants of diabetes in the young",
author = "Paul Dantonio and Nancy Meredith-Molloy and Hagopian, {William A.} and Jin-Xiong She and Beena Akolkar and Cordovado, {Suzanne K.} and Miyono Hendrix and Henderson, {L. Omar} and Hannon, {W. Harry} and Vogt, {Robert F.}",
year = "2010",
month = "1",
day = "1",
doi = "10.1177/193229681000400424",
language = "English (US)",
volume = "4",
pages = "929--941",
journal = "Journal of diabetes science and technology",
issn = "1932-2968",
publisher = "Diabetes Technology Society",
number = "4",

}

TY - JOUR

T1 - Proficiency testing of human leukocyte antigen-DR and human leukocyte antigen-DQ genetic risk assessment for type 1 diabetes using dried blood spots

AU - Dantonio, Paul

AU - Meredith-Molloy, Nancy

AU - Hagopian, William A.

AU - She, Jin-Xiong

AU - Akolkar, Beena

AU - Cordovado, Suzanne K.

AU - Hendrix, Miyono

AU - Henderson, L. Omar

AU - Hannon, W. Harry

AU - Vogt, Robert F.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Background: The plurality of genetic risk for developing type 1 diabetes mellitus (T1DM) lies within the genes that code for the human leukocyte antigens (HLAs). Many T1DM studies use HLA genetic risk assessment to identify higher risk individuals, and they often conduct these tests on dried blood spots (DBSs) like those used for newborn bloodspot screening. One such study is The Environmental Determinants of Diabetes in the Young (TEDDY), a long-term prospective study of environmental risk factors. To provide quality assurance for T1DM studies that employ HLA genetic risk assessment, the Centers for Disease Control and Prevention (CDC) conducts both a voluntary quarterly proficiency testing (VQPT) program available to any laboratory and a mandatory annual proficiency testing (PT) challenge for TEDDY laboratories. Methods: Whole blood and DBS samples with a wide range of validated HLA-DR and HLA-DQ genotypes were sent to the participating laboratories. Results were evaluated on the basis of both the reported haplotypes and the HLA genetic risk assessment. Results: Of the reported results from 24 panels sent out over six years in the VQPT, 94.7% (857/905) were correctly identified with respect to the relevant HLA-DR or HLA-DQ alleles, and 96.4% (241/250) were correctly categorized for risk assessment. Significant improvement was seen over the duration of this program, usually reaching 100% correct categorization during the last three years. Of 1154 reported results in four TEDDY PT challenges, 1153 (99.9%) were correctly identified for TEDDY eligibility. Conclusions: The different analytical methods used by T1DM research centers all provided accurate (>99%) results for genetic risk assessment. The two CDC PT programs documented the validity of the various approaches to screening and contributed to overall quality assurance.

AB - Background: The plurality of genetic risk for developing type 1 diabetes mellitus (T1DM) lies within the genes that code for the human leukocyte antigens (HLAs). Many T1DM studies use HLA genetic risk assessment to identify higher risk individuals, and they often conduct these tests on dried blood spots (DBSs) like those used for newborn bloodspot screening. One such study is The Environmental Determinants of Diabetes in the Young (TEDDY), a long-term prospective study of environmental risk factors. To provide quality assurance for T1DM studies that employ HLA genetic risk assessment, the Centers for Disease Control and Prevention (CDC) conducts both a voluntary quarterly proficiency testing (VQPT) program available to any laboratory and a mandatory annual proficiency testing (PT) challenge for TEDDY laboratories. Methods: Whole blood and DBS samples with a wide range of validated HLA-DR and HLA-DQ genotypes were sent to the participating laboratories. Results were evaluated on the basis of both the reported haplotypes and the HLA genetic risk assessment. Results: Of the reported results from 24 panels sent out over six years in the VQPT, 94.7% (857/905) were correctly identified with respect to the relevant HLA-DR or HLA-DQ alleles, and 96.4% (241/250) were correctly categorized for risk assessment. Significant improvement was seen over the duration of this program, usually reaching 100% correct categorization during the last three years. Of 1154 reported results in four TEDDY PT challenges, 1153 (99.9%) were correctly identified for TEDDY eligibility. Conclusions: The different analytical methods used by T1DM research centers all provided accurate (>99%) results for genetic risk assessment. The two CDC PT programs documented the validity of the various approaches to screening and contributed to overall quality assurance.

KW - Newborn screening

KW - Quality assurance

KW - Quality control

KW - The environmental determinants of diabetes in the young

UR - http://www.scopus.com/inward/record.url?scp=78049493498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049493498&partnerID=8YFLogxK

U2 - 10.1177/193229681000400424

DO - 10.1177/193229681000400424

M3 - Article

VL - 4

SP - 929

EP - 941

JO - Journal of diabetes science and technology

JF - Journal of diabetes science and technology

SN - 1932-2968

IS - 4

ER -